It’s How You Look at the Vial
What’s in a biosimilar name? That depends on whether the vial is half empty or half full. Seeing it as half full, many generic makers focus on the similarities between a follow-on and its reference biologic. Because of those similarities,…
Spittin’ Image: Or, How I Am Probably Going to Die
“Once you obtain your genetic information, the knowledge is irrevocable,” warn the service terms at saliva-testing firm 23andMe.com. The news wasn’t so bad, except for Alzheimer’s. Also, I’m sort of related to Stephen Colbert. Of course, 23andMe, of Mountain View,…
Playing Truth and Consequences with NIH Grants
When it comes to the National Institutes of Health’s (NIH) funding for medical research, it’s not a matter of truth or consequences. It’s more like truth and unintended consequences. Cheered on by prominent researchers, the NIH has embarked on an…
Bubbleology and Biotech’s Bull Run
Our recent analysis of biotech’s second quarter performance showed, for public biotech companies at least, their bull run that began more than 18 months ago is showing no signs of slowing down. Since the beginning of 2012 the Nasdaq Biotechnology…
History, Mystery, Gastronomy in the Mix in BioWorld’s 7th Annual Biotech Summer Reading List
With the official start of summer just around the corner, BioWorld again polled industry execs and our own indefatigable staff to construct a diverse list of titles for your reading pleasure. Whether the summer solstice takes you to a deck…
Oh, Give it Iressa! Nope: ‘Bad Pharma’ Firms Need to Tell More
So urgently did I think I wanted to read Ben Goldacre’s Bad Pharma, that I ordered it from Amazon’s UK site last November, unwilling to wait for U.S. publication – which happened just as I reached the end, polishing off…
Patients Want More than Check-the-Box Experience
Patients getting their four minutes to say how an experimental drug changed their life or gave them hope have become a routine part of nearly every FDA advisory committee meeting – as routine as the call to order or the…
Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, Finally
It’s been 16 years since I first reported in BioWorld Today that David Blech was charged with securities fraud. In April 1997, I reached him at his New York office a few days after his arraignment in a U.S. District…
Where’s Superman When He’s Needed?
Look! Up in the sky! It’s a bird! It’s a plane! It’s . . . another superbug. The invasion of the multidrug-resistant superbugs is not a nightmare in the making. It’s already here. And it could be years before a…
Biopeople to Meet at BIO2013: Inside the World of Biotech’s Luminaries, Titans and Brainiacs
Partnering, networking and making new friends are all top-of-the-agenda for the biopharma industry’s largest U.S. gathering. As you’re preparing to join 16,500+ of your colleagues at the 2013 BIO International Convention in Chicago, we’d like to introduce you to a…
